Cardiotoxicity – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Cardiotoxicity is a comprehensive term that covers a wide range of effects on the heart, including detectable structural alterations without symptoms, leading to arrhythmias, increased cardiac biomarkers due to stress and heart injury, and both systolic and diastolic dysfunction in the left ventricle, even without signs of heart failure. Cardiotoxicity is a well-recognized complication of fluoropyrimidines, namely 5-fluorouracil and its oral prodrug capecitabine. The risk of this adverse effect is heightened in patients undergoing thoracic radiation therapy simultaneously with multiagent chemotherapy, particularly if there's preexisting cardiac disease. The incidence of cardiotoxicity can be as high as 18% among individuals exposed to fluoropyrimidines. Cardiac toxicity can present in two forms, reversible or irreversible. Reversibility denotes the ability to regain cellular or organ function. However, certain myocardial changes, such as loss of myocardial cells through necrosis or apoptosis, loss of myofibrils, and deterioration of mitochondria, are generally considered irreversible in cellular or tissue damage. As per the cardiac review committee's assessment, drug-induced cardiotoxicity, specifically cardiomyopathy, involves one or more of the following criteria: (i) a reduction in left ventricular ejection fraction (LVEF), either throughout the ventricle or more prominently in the septum; (ii) indications and symptoms of heart failure, such as rapid heartbeat and S3 gallop; (iii) a decrease in LVEF that ranges from equal to or greater than 10% but less than 55%, without accompanying signs and symptoms of heart failure, or an LVEF decrease from equal to or less than 5% but less than 55%, combined with signs and symptoms of heart failure.
Thelansis’s “Cardiotoxicity Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Cardiotoxicity treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
KOLs insights
of Cardiotoxicity across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Cardiotoxicity Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment